Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma
- PMID: 32292497
- PMCID: PMC7150494
- DOI: 10.7150/thno.43251
Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma
Abstract
Rationale: Dietary exposure to aristolochic acids and similar compounds (collectively, AA) is a significant risk factor for nephropathy and subsequent upper tract urothelial carcinoma (UTUC). East Asian populations, who have a high prevalence of UTUC, have an unusual genome-wide AA-induced mutational pattern (COSMIC signature 22). Integrating mutational signature analysis with clinicopathological information may demonstrate great potential for risk ranking this UTUC subtype. Methods: We performed whole-genome sequencing (WGS) on 90 UTUC Chinese patients to extract mutational signatures. Genome sequencing data for urinary cell-free DNA from 26 UTUC patients were utilized to noninvasively identify the mutational signatures. Genome sequencing for primary tumors on 8 out of 26 patients was also performed. Metastasis-free survival (MFS) and cancer-specific survival (CSS) were measured using Kaplan-Meier methods. Results: Data analysis showed that a substantial proportion of patients harbored the AA mutational signature and were associated with AA-containing herbal drug intake, female gender, poor renal function, and multifocality. Field cancerization was found to partially contribute to multifocality. Nevertheless, AA Sig subtype UTUC patients exhibited favorable outcomes of CSS and MFS compared to the No-AA Sig subtype. Additionally, AA Sig subtype patients showed a higher tumor mutation burden, higher numbers of predicted neoantigens, and infiltrating lymphocytes, suggesting the potential for immunotherapy. We also confirmed the AA signature in AA-treated human renal tubular HK-2 cells. Notably, the AA subtype could be ascertained using a clinically applicable sequencing strategy (low coverage) in both primary tumors and urinary cell-free DNA as a basis for therapy selection. Conclusion: The AA mutational signature as a screening tool defines low-risk UTUC with therapeutic relevance. The AA mutational signature, as a molecular prognostic marker using either ureteroscopy and/or urinary cell-free DNA, is especially useful for diagnostic uncertainty when kidney-sparing treatment and/or immune checkpoint inhibitor therapy were considered.
Keywords: aristolochic acids; clinical outcome; mutational signature; upper tract urothelial carcinoma; whole-genome sequencing.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
Similar articles
-
Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.Sci Transl Med. 2013 Aug 7;5(197):197ra101. doi: 10.1126/scitranslmed.3006086. Sci Transl Med. 2013. PMID: 23926199
-
Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.Sci Transl Med. 2013 Aug 7;5(197):197ra102. doi: 10.1126/scitranslmed.3006200. Sci Transl Med. 2013. PMID: 23926200 Free PMC article.
-
Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.Int J Cancer. 2013 Jul;133(1):14-20. doi: 10.1002/ijc.28013. Epub 2013 Feb 12. Int J Cancer. 2013. PMID: 23292929
-
Molecular aspects of upper tract urothelial carcinoma.Urol Oncol. 2014 Jan;32(1):28.e11-20. doi: 10.1016/j.urolonc.2012.10.002. Epub 2013 Feb 19. Urol Oncol. 2014. PMID: 23428541 Review.
-
Mutational signature of aristolochic acid: Clue to the recognition of a global disease.DNA Repair (Amst). 2016 Aug;44:205-211. doi: 10.1016/j.dnarep.2016.05.027. Epub 2016 May 20. DNA Repair (Amst). 2016. PMID: 27237586 Review.
Cited by
-
Transcriptomic insights into UTUC: role of inflammatory fibrosis and potential for personalized treatment.J Transl Med. 2024 Jan 5;22(1):24. doi: 10.1186/s12967-023-04815-y. J Transl Med. 2024. PMID: 38183115 Free PMC article.
-
The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response.Cancer Med. 2023 Dec;12(24):22370-22380. doi: 10.1002/cam4.6725. Epub 2023 Nov 20. Cancer Med. 2023. PMID: 37986697 Free PMC article.
-
No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy.Chin J Integr Med. 2024 Feb;30(2):99-106. doi: 10.1007/s11655-023-3560-0. Epub 2023 Nov 9. Chin J Integr Med. 2024. PMID: 37943487
-
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.Nat Rev Urol. 2023 Jul;20(7):406-419. doi: 10.1038/s41585-023-00725-2. Epub 2023 Mar 28. Nat Rev Urol. 2023. PMID: 36977797 Review.
-
HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population.Oncologist. 2023 Aug 3;28(8):e617-e624. doi: 10.1093/oncolo/oyad070. Oncologist. 2023. PMID: 36971495 Free PMC article.
References
-
- Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M. et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111–22. - PubMed
-
- Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol. 2015. - PubMed
-
- Yang MH, Chen KK, Yen CC, Wang WS, Chang YH, Huang WJ. et al. Unusually high incidence of upper urinary tract urothelial carcinoma in taiwan. Urology. 2002;59:681–7. - PubMed
-
- Hsiao PJ, Hsieh PF, Chang CH, Wu HC, Yang CR, Huang CP. Higher risk of urothelial carcinoma in the upper urinary tract than in the urinary bladder in hemodialysis patients. Ren Fail. 2016;38:663–70. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources